医学
2型神经纤维瘤病
耐受性
内科学
不利影响
血管内皮生长因子
临床终点
贝伐单抗
不良事件通用术语标准
外科
肿瘤科
胃肠病学
神经鞘瘤
化疗
血管内皮生长因子受体
临床试验
作者
Ryota Tamura,Yoshiharu Yamanobe,Masato Fujioka,Yukina Morimoto,Mariko Fukumura,Masato Nakaya,Yumiko Oishi,Mizuto Sato,Ryo Ueda,Hirokazu Fujiwara,Tetsuro Hikichi,Shinobu Noji,Naoki Oishi,Hiroyuki Ozawa,Kaoru Ogawa,Yutaka Kawakami,Takayuki Ohira,Kazunari Yoshida,Masahiro Toda
摘要
The humanized antivascular endothelial growth factor (VEGF) antibody bevacizumab (Bev) is efficacious for the treatment of NF2-related schwannomatosis (NF2), previously known as neurofibromatosis type 2. This study evaluated the safety and efficacy of a VEGF receptor (VEGFR) vaccine containing VEGFR1 and VEGFR2 peptides in patients with NF2 with progressive schwannomas (jRCTs031180184).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
Nole
潇洒的惋清
cdercder
我能私信骂你吗
v0id
简单海露
OK
秋风
dde
xing_xing
aaaa
Dean
arniu2008
学术文献互助
DOC_XIONG
诸军则
wulanshu
DW
Criminology34
皖公网安备34019202002308
